WESTMINSTER, Colo., Feb. 27 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (Nasdaq: ALTH), today announced that it will report its
fourth quarter and 2006 financial results on Monday, March 5, 2007, before
the open of the U.S. financial markets.
Paul L. Berns, President and Chief Executive Officer, and other members
of Allos' senior management will provide a company update and review 2006
results via webcast and conference call on Monday, March 5, 2007 at 11:00
AM ET. The dial in number for U.S. residents to participate is
877-407-8031. International callers should dial 201-689-8031. Participants
should reference the Allos Therapeutics conference call. An audio replay of
the conference call will be available from 5 PM ET on Monday, March 5,
2007, until 11:59 PM ET on Thursday, March 15, 2007. To access the replay,
please dial 877-660- 6853 (domestic) or 201-612-7415 (international);
Replay pass codes (both required for playback): account # 286; conference
ID # 231653. The webcast of this call will be available from the homepage
and the investors/media section of the company's web site, http://www.allos.com
and will be archived for 30 days.
About Allos Therapeutics, Inc.
Allos Therapeutics, Inc. (ALTH) is a biopharmaceutical company focused
on the development and commercialization of small molecule therapeutics for
the treatment of cancer. The company has two product candidates in
late-stage clinical development: EFAPROXYN(TM) (efaproxiral), a radiation
sensitizer currently under evaluation in a pivotal Phase 3 trial in women
with brain metastases originating from breast cancer, and PDX
(pralatrexate), a novel, next generation antifolate currently under
evaluation in a pivotal Phase 2 trial in patients with relapsed or
refractory peripheral T-cell lymphoma. The company is also evaluating RH1,
a targeted chemotherapeutic agent, in a Phase 1 trial in patients with
advanced solid tumors. For additional information, please visit the
company's website at http://www.allos.com.
Safe Harbor Statement
The 2006 fourth quarter results press release and conference call will
contain forward-looking statements that involve significant risks and
uncertainties, including those contained in the "Risk Factors" section of
the company's Annual Report on Form 10-K for the year ended December 31,
2005 and in the company's other periodic reports and filings with the
Securities and Exchange Commission. Allos is providing the information
contained in the press release and conference call as of the date of the
release and does not undertake any obligation to update any forward-
looking statements as a result of new information, future events or
otherwise. The company cautions investors not to place undue reliance on
the forward- looking statements contained in the press release or the
conference call. No forward-looking statement can be guaranteed and actual
events and results may differ materially from those projected.
SOURCE Allos Therapeutics, Inc.
 back to top
Related links:
http://www.allos.com
CONTACT:
Jennifer Neiman, Manager, Corporate
Communications of Allos Therapeutics, +1-720-540-5227,
jneiman@allos.com
|
